Mapping of The Biosimilar Drug Policy in 10 Central Eastern European Countries

Abstract

flows and the required cost of capital, can be used to validate the price of the new drug from a narrow investor's perspective. The free cash flow represent the sales from the pharmaceuticals, and cash necessary for capital expenditures represent the costs for research & development (R&D) and marketing. The cost of capital refers to the opportunity cost of making a specific investment, which is the rate of return required to persuade the investor to make a given investment. Conclusion: We propose a policy approach for the evaluation of innovative drugs by bridging concepts from health economics and business economic valuation. This approach may justify a drug price from an investor's perspective when the ICER exceeds the threshold and may be used in negotiations between governments and companies.

Drug Retention and Safety of Secukinumab in a Real-World Cohort of Ankylosing Spondylitis and Psoriatic Arthritis Patients

“…An illustrative study has provided evidence for this claim, and has shown that biologic drug availability varies substantially across countries and healthcare [ 14 ]. Other reports, and our own epidemiologic studies have shown that studies in a given demographic are especially warranted, as the projected estimates extrapolated from other studies often do not fall in line with first-hand evidence [ 14 , 15 , 16 , 17 , 18 , 19 ]. Moreover, the importance of this study is justified by the limited therapeutic armamentarium currently available in Poland.…”

Policy Practices to Maximise Social Benefit from Biosimilars

“…To respond to this political pressure several biologic medicines not meeting local cost-effective thresholds are reimbursed in lower income European countries, however various access restrictions are implemented to ensure the sustainability of health care financing [16]. These restrictions can influence prescribers, patients and manufacturers.…”